Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) such as semaglutide and liraglutide produce significant weight loss (≥10%) and cardiovascular benefits in adults with obesity.
GLP-1 receptor agonists like semaglutide are highly effective for weight loss, often achieving 10% or more body weight reduction, and also provide cardiovascular benefits. These medications are available in both injectable and oral forms, offering flexibility for long-term management of obesity.
StrongSupportsVERY_HIGH confidence
The therapeutic landscape for GPCR as targets of anti-obesity medications has undergone significant changes with the approval of semaglutide, the first peptide glucagon like peptide 1 receptor agonist (GLP-1RA) achieving double digit weight loss (≥10%) and cardiovascular benefits.
Why this rating
The paper cites multiple large-scale clinical trials (SELECT trial, STEP 8) and FDA approvals.
Source
G protein-coupled receptors and obesity
Alessandro Pocai · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1301017
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual or triple agonists targeting GLP-1, GIP, and/or Glucagon receptors (GCGR) produce superior weight loss compared to selective GLP-1 receptor agonists alone.Good
- Rapid weight loss from GLP-1 and dual/triple agonists can lead to significant loss of lean muscle mass, necessitating strategies to preserve muscle.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →